9th Sep 2020 13:33
Redx Pharma PLC - drug discovery firm - Signs a new research collaboration agreement with Jazz Pharmaceuticals PLC - Irish biopharmaceutical company - to discover and develop drug candidates for two cancer targets on the Ras/Raf/MAP kinase pathway. Redx says it will be responsible for research and preclinical development activities up to investigational new drug submission. Under the terms of the agreement, Jazz will pay Redx an upfront payment of USD10 million followed by another USD10 million in year two provided research work is continuing. Following delivery of an investigational new drug-ready molecule, Redx will be eligible to receive up to a further USD200 million from Jazz in development, regulatory and commercial milestone payments1 for each programme.
Current stock price: 61.00 pence
Year-to-date change: multiplied from 8.0p
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
REDX.L